Facebook
Twitter
LinkedIn
ForwardCardiac Radioablation for Ventricular Tachycardia
Patients with high-risk ventricular tachycardia (VT) refractory to standard therapies (anti-arrhythmic drugs, catheter ablation) and multiple cardiovascular risk factors have poor survival and high rates of recurrent VT. Noninvasive cardiac radioablation using a single dose of SBRT to the VT substrate in the myocardium has shown promising results in a single Phase I/II trial and multiple case series. A number of elements of this new treatment remain in flux, including optimal patient selection, methods for targeting, methods for motion management, direct comparisons with catheter ablation, new findings around the biological underpinnings of cardiac radioablation, and evolving regulatory and billing issues.
Presenters: Daniel H. Cooper, MD; Geoff Hugo, MD; Kaitlin Moore; Pamela Samson, MD, MPHS
Moderator: Malcolm Mattes, MD
This session was originally presented and recorded as a live webinar on September 9, 2024.
Target Audience
This activity is designed to meet the interests of radiation oncologists, radiation physicists, radiation dosimetrists, radiation biologists, radiation therapists, diagnostic radiologists, nurses, emergency physicians, and radiation oncology residents.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Define the target patient population for cardiac radioablation.
- Describe the key elements required to define a cardiac radioablation target volume.
- Describe expected efficacy and toxicity outcomes following cardiac radioablation.
- Daniel H. Cooper, MD is employed by Washington University in St. Louis. Dr. Cooper receives travel expenses and pay/compensation as an Adivsory Board member for Medtronic; honoraria and travel expenses as education/meeting faculty for Abbott; and, honoraria and travel expenses as education/meeting faculty for Boston Scientific.
- Geoff Hugo, PhD is employed by Washington University in St. Louis. Dr. Hugo receives compensation as a consultant for Varian and research funding (institution) from Siemens and ViewRay. Dr. Hugo's institution has a copyright licensed to Varian Medical Systems.
- Katilin Moore is employed by Washington University in St. Louis.
- Pamela Samson, MD, MPHS is employed by Washington University in St. Louis. Dr. Samson receives honoraria and travel expenses as education/meeting faculty for Varian Medical Systems and honoraria as education/meeting faculty for AstraZeneca.
- Malcolm Mattes, MD is employed by the Rutgers Cancer Institute of New Jersey. Dr. Mattes is Vice Chair of the ASTRO Communications Committee.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.